Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 471 to 480 of 2450 total matches.
In Brief: Respiratory Depression with Gabapentinoids
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
-threatening or
fatal respiratory depression in patients with respiratory risk
factors.1 Respiratory risk ...
The FDA has required new warnings in the labels of
gabapentin (Neurontin, and others) and pregabalin (Lyrica,
Lyrica CR, and generics) about the risk of life-threatening or
fatal respiratory depression in patients with respiratory risk
factors. Respiratory risk factors include chronic obstructive
pulmonary disease (COPD) and concurrent use of opioids
or other CNS depressants. Elderly patients are also at
increased risk.
In Brief: Trijardy XR - A New 3-Drug Combination for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
instructions for starting
treatment are complex.
1. Empagliflozin (Jardiance) for diabetes. Med Lett Drugs ...
The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
cotransporter 2 (SGLT2) inhibitor empagliflozin, the
dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, and
extended-release metformin, for oral treatment of type 2
diabetes in adults. Empagliflozin and linagliptin have been
available in a fixed-dose combination as Glyxambi since
2015, and both have been available in 2-drug combinations
with extended-release metformin for years (see Table 1).
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 18, 2020 (Issue 1598)
-healthy diet such as the Dietary Approaches
to Stop Hypertension (DASH) diet,1 limiting intake
of sodium ...
Drugs available for treatment of chronic hypertension
and their dosages, adverse effects, and costs are
listed in the tables. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
a cephalosporin or a carbapenem with
a beta-lactamase inhibitor such as ceftazidime/
avibactam (Avycaz),1 ...
The FDA has approved cefiderocol (Fetroja – Shionogi),
a new IV cephalosporin antibiotic, for treatment of
complicated urinary tract infections (UTI) caused by
susceptible gram-negative bacteria in adults who
have limited or no alternative treatment options.
Minocycline Foam (Amzeeq) for Acne
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
tetracycline
is recommended because of its dual antibacterial
and anti-inflammatory activity.1,2 Monotherapy ...
The FDA has approved a 4% aerosol foam formulation
of minocycline (Amzeeq – Foamix) for topical
treatment of inflammatory lesions of non-nodular
moderate to severe acne in patients ≥9 years old. It is
the first topical tetracycline formulation to be approved
for use in patients with acne. Oral minocycline
(Minocin, Solodyn, and generics) is
In Brief: Neuropsychiatric Events with Montelukast
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
of suicidal behavior and other
serious neuropsychiatric events associated with its use.1
Montelukast ...
The FDA is requiring stronger warnings in the labeling of
the leukotriene receptor antagonist montelukast (Singulair,
and generics) about the risk of suicidal behavior and other
serious neuropsychiatric events associated with its use.
Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
(Ubrelvy),
which is approved for the same indication, was the
first.1 Four parenteral CGRP antagonists ...
The FDA has approved an orally disintegrating tablet
(ODT) formulation of rimegepant (Nurtec ODT –
Biohaven), a small-molecule calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant"), for
acute treatment of migraine with or without aura
in adults. Rimegepant is the second oral gepant to
become available in the US; ubrogepant (Ubrelvy),
which is approved for the same indication, was the
first. Four parenteral CGRP antagonists, erenumab
(Aimovig), fremanezumab (Ajovy), galcanezumab
(Emgality), and eptinezumab (Vyepti), are approved
for prevention of...
Drugs for Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020 (Issue 1596)
of osteoarthritis of the
hip, hand, and knee.1
NSAIDS
Nonsteroidal anti-inflammatory drugs (NSAIDs ...
Many different drugs are used for treatment of
osteoarthritis pain, but none of them prevent
progression of the disease. Nonpharmacologic
approaches including weight management, exercise,
tai chi, physical therapy, assistive devices, and total
joint arthroplasty can also be used. The American
College of Rheumatology (ACR) has published new
guidelines for the management of osteoarthritis of the
hip, hand, and knee.
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020 (Issue 1596)
time interval (6 to as long as 48
hours), with conscious recovery between seizures.1
Seizure clusters ...
The FDA has approved nasal spray formulations of
the benzodiazepines diazepam (Valtoco — Neurelis)
and midazolam (Nayzilam — UCB) for acute treatment
of intermittent episodes of frequent seizure activity
(seizure clusters). Diazepam rectal gel (Diastat, Diastat
AcuDial, and generics) has been used for this indication
for many years.
Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
) can further reduce LDL-C levels and the risk
of secondary cardiovascular events.1
MECHANISM ...
The FDA has approved the oral adenosine triphosphate-citrate
lyase (ACL) inhibitor bempedoic acid for
use alone (Nexletol – Esperion) and in a fixed-dose
combination with the cholesterol absorption inhibitor
ezetimibe (Nexlizet) as an adjunct to diet and maximally
tolerated statin therapy in adults with heterozygous
familial hypercholesterolemia (HeFH) or established
atherosclerotic cardiovascular disease (ASCVD) who
require additional lowering of LDL-cholesterol (LDL-C).
Bempedoic acid is the first ACL inhibitor to be approved
in the US.